A panelist discusses how an 83-year-old patient with diabetic macular edema (DME) who showed suboptimal response to standard anti-VEGF therapies, including aflibercept 2 mg and faricimab, ultimately ...
A panelist discusses how a 76-year-old patient with neovascular age-related macular degeneration (nAMD) initially stable on bevacizumab developed recurrent subretinal fluid requiring a switch to ...
Commercial shipments for VIZZ will begin in October, with availability in retail pharmacies expected by mid-Q4 2025. Following a US Food and Drug Administration approval back in July 2025, LENZ ...
Lupin’s subsidiary, Nanomi, has signed a definitive agreement to acquire VISUfarma, a portfolio company of GHO Capital Partners LLP. Lupin notes that the acquisition will help the company expand its ...
Temperature control during vitrectomy is crucial to prevent iatrogenic damage, especially in diabetic and myopic patients. Romano's device manages intraocular temperature and fluid exchange, ...
Treatment-Resistant AMD and Diabetic Macular EdemaWith High-Dose Aflibercept Summary. This presentation examines the management of treatment-resistant retinal conditions using hig ...
David Lally, MD, presented at the 2025 Retina Society meeting, discussing the ARCHER study (NCT04656561) of ANX007 for the treatment of age-related macular degeneration (AMD) and geographic atrophy ...
Opus Genetics today announced the positive 3-month pediatric data from its Phase 1/2 open-label, ascending-dose study of the safety and efficacy of OPGx-LCA5, an investigational gene therapy for Leber ...
Ultra High Resolution OCT offers detailed visualization of retinal structures, aiding in monitoring disease progression and assessing therapeutic interventions in conditions like age-related macular ...
Following the assembly of the prototype, the OCT researchers were able to present the first high-resolution images of the eye of a healthy volunteer just 2 years later, Professor Jakub Kałużny, MD, ...
The ACTOR study finds OCT angiography cannot predict exudative recurrence in neovascular AMD but offers valuable vascular remodeling insights. The HERMES study reveals worsening peripheral ...
The AVONELLE-X study confirms sustained visual gains and treatment durability of faricimab for wet AMD over four years. 80% of patients maintained extended treatment intervals, demonstrating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback